期刊
JOURNAL OF RHEUMATOLOGY
卷 40, 期 6, 页码 866-871出版社
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.121162
关键词
PSORIASIS; PSORIATIC ARTHRITIS; BIOMARKERS; TREATMENT; TUMOR NECROSIS FACTOR INHIBITORS
类别
资金
- Arthritis Society
- Canadian Institutes of Health Research (CIHR) Institute of Musculoskeletal Health and Arthritis
- Krembil Foundation
- CIHR Clinical Research Initiative Fellowship
- Abbott Canada
- CIHR
- Amgen Canada
- Janssen
Objective. To identify soluble biomarkers associated with response to therapy with tumor necrosis factor inhibitors (TNFi) in patients with psoriatic arthritis (PsA). Methods. The study was conducted at a PsA clinic where patients are assessed every 6 months, and serum samples are collected and stored once a year at the time of clinical assessment. Forty patients with active PsA who gave serum samples prior to treatment with TNFi and after at least 3 months of therapy were identified. Patients were classified as TNFi responders if tender joint count was <3, swollen joint count was 0, and Psoriasis Area and Severity Index score was <4 at the time the second sample was collected. The following biomarkers were tested by ELISA: TNF superfamily 14, matrix metalloprotease-3 (MMP-3), receptor activator of nuclear factor kappa-B ligand, osteoprotegerin, cartilage oligomeric matrix protein (COMP), CPU, C2C and C1-2C, CS-846, and highly sensitive C-reactive protein. Paired t tests and logistic regression was used for statistical analyses. Results. After a mean treatment duration of 11 months with TNFi (etanercept 28 patients, adalimumab 6, golimumab 4, infliximab 2), 29 patients were classified as TNFi responders. Baseline level of MMP-3 was independently associated with responder status (OR 1.067 for each 1-unit increase, p = 0.045). A reduction in MMP-3 levels with therapy increased the odds of achieving response (OR 1.213 for each 1-unit change, p = 0.030), whereas a reduction in COMP decreased the odds (OR 0.587, for each 100-unit increase, p = 0.039). None of the other biomarkers was associated with response. Conclusion. Baseline as well as reduction in serum MMP-3 and increase in serum COMP are independently associated with response to TNFi therapy in patients with PsA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据